
https://www.science.org/content/blog-post/not-quite-what-friends-are
# Not Quite What Friends Are For (February 2017)

## 1. SUMMARY
This commentary discusses the culture of confidentiality in industrial drug research, where scientists working at different pharmaceutical companies learn to avoid discussing proprietary details about their work. The author notes that this practice becomes especially important in competitive biotech hubs like Boston/Cambridge, where accidental disclosures can occur in everyday settings like public transportation or restaurants.

The article centers around a news story involving two friends working at different Cambridge biotech companies who were allegedly sharing material information about clinical trial announcements and using this insider knowledge for stock trading. The author compares this behavior to "helping yourself out of the cash register," emphasizing how obvious and risky such insider trading activities are, particularly when done repeatedly in an industry where proprietary information is so carefully guarded.

## 2. HISTORY
The case referenced in this article involves a 2017 insider trading scheme between two friends in Cambridge's biotech sector. Based on the details provided in the article and the linked Endpoints News story, this appears to involve federal charges related to material nonpublic information sharing between employees at different companies.

Subsequent developments in insider trading enforcement within biotech have shown a pattern of increasingly sophisticated detection methods. Between 2017-2024, the SEC and DOJ have brought numerous cases involving biotech and pharmaceutical insider trading, often targeting information about clinical trial results, FDA approvals, and merger/acquisition discussions. These cases have demonstrated that regulatory agencies have become more effective at detecting patterns of suspicious trading activity, particularly around major biotech announcements.

During this period, several high-profile biotech insider trading cases made headlines, though none appear to directly match the exact "two friends" scenario described. The industry has generally maintained its culture of strict confidentiality around clinical data and drug development timelines, recognizing both the competitive and legal implications of information leakage.

## 3. PREDICTIONS
The article contains several implicit predictions and observations about insider trading behavior:

**Prediction: Insider trading is an "obvious route to profit" that draws attention**
- **Accuracy**: ✓ Accurate - SEC enforcement data from 2017-2024 shows increased detection of biotech insider trading through data analytics and suspicious trading pattern recognition

**Prediction: People who succeed with insider trading once often "go back to the well again and again"**
- **Accuracy**: ✓ Accurate - Multiple documented cases show repeat offenders, and Wall Street trading behavior studies confirm this recidivist pattern in various insider trading prosecutions

**Observation: Geographic proximity in biotech hubs increases disclosure risk**
- **Accuracy**: ✓ Accurate - The concentration of biotech companies in Cambridge/Boston has continued to grow, maintaining the geographic risk factors mentioned

## 4. INTEREST
**Rating: 3/10**
The article addresses insider trading risks in biotech, which is a real phenomenon, but provides limited lasting insight beyond cautionary observations about human behavior and risk-taking in competitive environments.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20170209-not-quite-what-friends-are.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_